醫(yī)學(xué)全在線
醫(yī)學(xué)全在線首頁-醫(yī)師-藥師-護(hù)士-衛(wèi)生資格-高級(jí)職稱-考試題庫-網(wǎng)校-考研-圖譜-下載-招聘  
分類
國家級(jí)省級(jí)浙江省各省雜志
科技核心北大核心CSCDCSCD擴(kuò)展
工具
期刊知識(shí)寫作指導(dǎo) 論文投稿推薦期刊
期刊驗(yàn)證論文檢測(cè) 錄用通知往期目錄
SCI
SCI指導(dǎo)影響因子
期刊點(diǎn)評(píng)基金動(dòng)態(tài)
其它
經(jīng)濟(jì)教育計(jì)算機(jī)
建筑體育農(nóng)業(yè)
北京|天津|河北|山西|湖北|江蘇|安徽|山東|上海|浙江|江西|福建|湖南|寧夏|內(nèi)蒙古|河南
四川|重慶|貴州|云南|遼寧|吉林|廣東|廣西|海南|陜西|甘肅|新疆|青海|衛(wèi)生部直屬|黑龍江|兵團(tuán)
您現(xiàn)在的位置: 醫(yī)學(xué)全在線 > 醫(yī)學(xué)論文 > 論文投稿 > 正文:醫(yī)學(xué)免費(fèi)論文:參麥注射液聯(lián)合綜合心理干預(yù)在非小細(xì)胞肺癌化療中
    

醫(yī)學(xué)免費(fèi)論文:參麥注射液聯(lián)合綜合心理干預(yù)在非小細(xì)胞肺癌化療中

來源:本站原創(chuàng) 更新:2013-10-15 論文投稿平臺(tái)

醫(yī)學(xué)免費(fèi)論文:參麥注射液聯(lián)合綜合心理干預(yù)在非小細(xì)胞肺癌化療中

【摘要】 [目的]觀察參麥注射液(SMI)聯(lián)合綜合心理干預(yù)在晚期非小細(xì)胞肺癌(NSCLC)化療中的使用價(jià)值。[方法]晚期NSCLC 79例,治療組40例,采用常規(guī)化療配合參麥注射液聯(lián)合綜合心理干預(yù),并與單純化療的39例作對(duì)照,觀察兩組的體力狀況、療效、1年生存率、骨髓抑制情況等。[結(jié)果]治療組和對(duì)照組的Karnofsky評(píng)分提高+穩(wěn)定率為75.0%及46.2%、療效穩(wěn)定以上率(CR+PR+NC)為70.0%及46.2%,1年生存率為47.5%及25.6%。治療組與對(duì)照
組的Ⅱ度以上的白細(xì)胞下降的發(fā)生率分別為32.5%及53.8%(P=0.032),Ⅱ度以上的血小板下降的發(fā)生率分別為30.0%及46.2%(P=0.032),之間的差異均有統(tǒng)計(jì)學(xué)意義。[結(jié)論]治療組的Karnofsky評(píng)分、療效穩(wěn)定以上率、1年生存率、骨髓抑制發(fā)生率均優(yōu)于對(duì)照組,提示SMI及心理干預(yù)聯(lián)合化療治療晚期NSCLC有增效減毒作用。

【關(guān)鍵詞】  參麥注射液;非小細(xì)胞肺癌;綜合心理干預(yù);

The Role of Shenmai Injection Combined withPsychotherapy in Chemotherapy of Nonsmall Cell

Lung CancerNi Bingqiang,Zhang Zhihong,Wu Meijuan,et al

The Fifth Affiliated Hospital of GuangxiMedical College,Liuzhou(545006),China

Abstract:[Objective]To evaluate the efficacyof Shenmai injection combined with psychotherapy inchemotherapy of nonsmall cell lung cancer.[Method]79 cases of advanced nonsmall cell lungcancer were randomly divided into two groups,40cases in observation group with Shenmai injectioncombined with chemotherapy and psychotherapy,39cases in control group with chemotherapy alone.TheKarnofsky scores,therapeutic efficacy,one yearsurvival rate and incidence of myelosuppressionwere evaluated.[Result] The two groups weresignificantly different in Karnofsky scores,therapeutic efficacy and one year survival rate.Theimprovement and stability rate of Karnofsky scoresand that of therapeutic efficacy were 75.0% and70.0% in observation group,with 46.2% and 46.2% incontrol group,respectively.One year survival ratewas 47.5% in observation group and 25.6% in controlgroup,respectively.The incidence ofmyelosuppression had significant differences in thetwo groups,with grade 2~4 leucopenia 32.5% inobservation group and 53.8% in control group(P=0.032),with grade 2~3 thrombocytopenia 30.0%in observation group and 46.2% in control group(P=0.032).[Conclusion] Combination treatment inobservation group was superior to the treatment incontrol group,with a higher Karnofsky scores,moreeffective therapy,a higher one year survival rateand a lower incidence of myelosuppression.Thetreatment of Shenmai injection combind withchemotherapy could reduce toxicity and enhancetherapeutic efficacy.

Key words: Shenmai injection(SMI);nonsmallcell lung cancer;psychotherapy;chemotherapy 

Ⅲb、Ⅳ期非小細(xì)胞肺癌(NSCLC)化療的價(jià)值已得到肯定,但因其高癥狀負(fù)荷和高流失率等[1],所以對(duì)癥中藥及心理干預(yù)等綜合治療仍占重要地位。我們采用參麥注射液(SMI)配合心理干預(yù)以期緩解癥狀,提高生存質(zhì)量,增加其對(duì)化療的依從性等,取得了較好效果,現(xiàn)報(bào)道如下醫(yī).學(xué).全.在.線m.quanxiangyun.cn

1  臨床資料


[1] [2] [3] [4] 下一頁

...
關(guān)于我們 - 聯(lián)系我們 -版權(quán)申明 -誠聘英才 - 網(wǎng)站地圖 - 網(wǎng)絡(luò)課程 - 幫助
醫(yī)學(xué)全在線 版權(quán)所有© CopyRight 2006-2046, MED126.COM, All Rights Reserved
浙ICP備12017320號(hào)
百度大聯(lián)盟認(rèn)證綠色會(huì)員實(shí)名網(wǎng)站 360認(rèn)證可信網(wǎng)站 中網(wǎng)驗(yàn)證